{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:09:50Z","timestamp":1762603790058,"version":"3.40.3"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,11,1]]},"DOI":"10.1093\/chromsci\/bms088","type":"journal-article","created":{"date-parts":[[2012,6,8]],"date-time":"2012-06-08T01:23:12Z","timestamp":1339118592000},"page":"902-908","source":"Crossref","is-referenced-by-count":10,"title":["High-Performance Liquid Chromatographic Assay for Ziprasidone in Plasma Samples: Application to Pharmacokinetic Studies in Rats"],"prefix":"10.1093","volume":"50","author":[{"given":"Swapnil","family":"Marghade","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashant B.","family":"Musmade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudheer","family":"Moorkoth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2012,6,7]]},"reference":[{"key":"key\n\t\t\t\t20171011222043_BMS088C1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1345\/aph.1A053","article-title":"Ziprasidone: The fifth atypical antipsychotic","volume":"36","author":"Caley","year":"2002","journal-title":"Annals of Pharmacotherapy"},{"issue":"1","key":"key\n\t\t\t\t20171011222043_BMS088C2","doi-asserted-by":"crossref","first-page":"43S","DOI":"10.1046\/j.1365-2125.2000.00152.x","article-title":"Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers","volume":"49","author":"Wilner","year":"2000","journal-title":"British Journal of Clinical Pharmacology"},{"key":"key\n\t\t\t\t20171011222043_BMS088C3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-3565(25)12023-5","article-title":"Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity","volume":"275","author":"Seeger","year":"1995","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"key\n\t\t\t\t20171011222043_BMS088C4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0014-2999(01)01188-8","article-title":"Ziprasidone: A novel antipsychotic agent with a unique human receptor binding profile","volume":"425","author":"Schmidt","year":"2001","journal-title":"European Journal of Pharmacology"},{"key":"key\n\t\t\t\t20171011222043_BMS088C5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1365-2125.2000.00148.x","article-title":"Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers","volume":"49","author":"Wilner","year":"2000","journal-title":"British Journal of Clinical Pharmacology"},{"key":"key\n\t\t\t\t20171011222043_BMS088C6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1365-2125.2000.00147.x","article-title":"Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers","volume":"49","author":"Miceli","year":"2000","journal-title":"British Journal of Clinical Pharmacology"},{"key":"key\n\t\t\t\t20171011222043_BMS088C7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/bmc.299","article-title":"Stability indicating reversed phase high-performance liquid chromatographic and thin layer densitometric methods for the determination of ziprasidone in bulk powder and in pharmaceutical formulations","volume":"18","author":"El-Sherif","year":"2004","journal-title":"Biomedical Chromatography"},{"key":"key\n\t\t\t\t20171011222043_BMS088C8","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1365\/s10337-006-0125-2","article-title":"A rapid stability-indicating LC method for ziprasidone hydrochloride","volume":"65","author":"Singh","year":"2007","journal-title":"Chromatographia"},{"key":"key\n\t\t\t\t20171011222043_BMS088C9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jchromb.2007.05.015","article-title":"Simultaneous estimation of five antipsychotic drugs in rat plasma by high performance liquid chromatography with ultraviolet detection","volume":"856","author":"Zhang","year":"2007","journal-title":"Journal of Chromatography B"},{"key":"key\n\t\t\t\t20171011222043_BMS088C10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jchromb.2003.10.027","article-title":"Determination of plasma ziprasidone using liquid chromatography with fluorescence detection","volume":"799","author":"Suckowa","year":"2004","journal-title":"Journal of Chromatography B"},{"key":"key\n\t\t\t\t20171011222043_BMS088C11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/01.ftd.0000150879.36296.4d","article-title":"Automated determination of ziprasidone by HPLC with column switching and spectrophotometric detection","volume":"27","author":"Sachse","year":"2005","journal-title":"Therapeutic Drug Monitoring"},{"key":"key\n\t\t\t\t20171011222043_BMS088C12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0378-4347(95)00071-P","article-title":"Development and validation of a high-sensitivity assay for an antipsychotic agent, CP-88,059, with solid-phase extraction and narrow-bore high-performance liquid chromatography","volume":"668","author":"Janiszewski","year":"1995","journal-title":"Journal of Chromatography B"},{"key":"key\n\t\t\t\t20171011222043_BMS088C13","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/bmc.571","article-title":"Rapid liquid chromatography\u2013tandem mass spectrometry method for quantification of ziprasidone in human plasma","volume":"20","author":"Al-Dirbashi","year":"2006","journal-title":"Biomedical Chromatography"},{"key":"key\n\t\t\t\t20171011222043_BMS088C14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jchromb.2006.10.024","article-title":"Determination of ziprasidone in human plasma by liquid chromatography\u2013electrospray tandem mass spectrometry and its application to plasma level determination in schizophrenia patients","volume":"847","author":"Aravagiri","year":"2007","journal-title":"Journal of Chromatography B"},{"key":"key\n\t\t\t\t20171011222043_BMS088C15","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/bmc.999","article-title":"Determination of the lipophilic antipsychotic drug ziprasidone in rat plasma and brain tissue using liquid chromatography\u2013tandem mass spectrometry","volume":"22","author":"Zhang","year":"2008","journal-title":"Biomedical Chromatography"},{"key":"key\n\t\t\t\t20171011222043_BMS088C16","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1365\/s10337-010-1725-4","article-title":"Determination of ziprasidone by UPLC-MS-MS and its application to a pharmacokinetic study of Chinese schizophrenics","volume":"72","author":"Yan-Qing","year":"2010","journal-title":"Chromatographia"},{"key":"key\n\t\t\t\t20171011222043_BMS088C17","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jchromb.2007.08.007","article-title":"Sensitive liquid chromatography\/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissue","volume":"858","author":"Zhang","year":"2007","journal-title":"Journal of Chromatography B"},{"key":"key\n\t\t\t\t20171011222043_BMS088C18","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/rcm.2914","article-title":"Liquid chromatography\/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat plasma","volume":"21","author":"Zhang","year":"2007","journal-title":"Rapid Communications in Mass Spectrometry"},{"key":"key\n\t\t\t\t20171011222043_BMS088C19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.talanta.2010.04.036","article-title":"Electroanalytical characteristics of antipsychotic drug ziprasidone and its determination in pharmaceuticals and serum samples on solid electrodes","volume":"82","author":"Kul","year":"2010","journal-title":"Talanta"},{"author":"Guidance for Industry: Bioanalytical method validation (May 2001); U. S. Department of health and human services, Food and drug administration","key":"key\n\t\t\t\t20171011222043_BMS088C20"},{"key":"key\n\t\t\t\t20171011222043_BMS088C21","first-page":"206","article-title":"Metabolism and excretion of the novel antipsychotic drug ziprasidone in rats after oral administration of a mixture of 14C- and 3H- labelled ziprasidone","volume":"25","author":"Prakash","year":"1997","journal-title":"Drug Metabolism and Disposition"}],"container-title":["Journal of Chromatographic Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/chromsci\/article-pdf\/50\/10\/902\/983611\/bms088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T05:39:40Z","timestamp":1743313180000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/chromsci\/article\/50\/10\/902\/343894\/HighPerformance-Liquid-Chromatographic-Assay-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,7]]},"references-count":21,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2012,6,7]]},"published-print":{"date-parts":[[2012,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/chromsci\/bms088","relation":{},"ISSN":["1945-239X","0021-9665"],"issn-type":[{"type":"electronic","value":"1945-239X"},{"type":"print","value":"0021-9665"}],"subject":[],"published-other":{"date-parts":[[2012,11]]},"published":{"date-parts":[[2012,6,7]]}}}